Physician profile
Karim Samara
NPI 1700844420
$3,161.37
in general payments reported to CMS, 2019-2025
29 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $357 · 2021: $376 · 2022: $334 · 2023: $366 · 2024: $335 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.25 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $612.70 | 2019-2025 | Tryptyr, Hydrus Microstent, Clareon |
| Allergan, INC. | $438.95 | 2019-2022 | |
| Sight Sciences, INC. | $326.02 | 2019-2025 | Omni Surgical System |
| Abbvie INC. | $176.89 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Sun Pharmaceutical Industries INC. | $169.75 | 2019-2025 | Cequa, Xelpros |
| Rxsight INC | $141.73 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Johnson & Johnson Surgical Vision, INC. | $121.74 | 2021-2025 | Tecnis Simplicity, Tecnis Iol, Catalys System |
| Harrow Eye, LLC | $120.29 | 2024-2025 | Vevye |
| Alcon Research LLC | $112.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $105.30 | 2019-2023 | |
| Rayner Intraocular Lenses Limited | $104.08 | 2022-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Dompe US, INC. | $103.76 | 2024-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $84.40 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Horizon Therapeutics Plc | $82.28 | 2021-2023 | Tepezza |
| Halozyme INC | $72.06 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $63.84 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $56.16 | 2022-2023 | Tyrvaya |
| Ivantis, INC | $45.48 | 2020 | |
| Aerie Pharmaceuticals, INC. | $42.44 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $42.14 | 2021-2022 | |
| Masimo Corporation | $20.73 | 2023 | Set and Rainbow Set |
| Glaukos Corporation | $17.95 | 2024 | Idose |
| Ocular Therapeutix, INC. | $17.70 | 2024 | Dextenza |
| Alimera Sciences, INC. | $17.39 | 2021 | |
| Shire North American Group INC | $16.94 | 2019 | |
| Amgen INC. | $16.69 | 2024 | Tepezza |
| Biotissue Holdings INC. | $14.53 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.08 | 2019 | |
| New World Medical,INC. | $5.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karim Samara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.